Klotho is advancing its ALS gene therapy candidate KLTO‑202 to the manufacturing phase, and is planning the first human ...

BrainStorm Cell Therapeutics issued a statement Tuesday supporting a Citizens’ Petition submitted to the FDA requesting the ...

BrainStorm to Continue with Planned Phase 3b Trial and Remains Committed to Advancing Access for People Living with ALS NEW YORK, July 8, 2025 /PRNewswire/ -- BrainStorm ...

A new study links common mental health drugs to a higher ALS risk. The research focused on anxiolytics, hypnotics, and ...

Commonly prescribed medications for anxiety, depression and sleep disorders may be associated with a higher risk of ...

JJ Potrikus, vice president of the New York Collegiate Baseball League, joined Bridge Street for details this morning along ...

The FDA granted orphan drug designation to Sineugene Therapeutics' SNUG01, a first-in-class experimental gene therapy for ...

On July 4, 1776, the Continental Congress adopted the Declaration of Independence, proclaiming U.S. independence from Britain ...

A team of researchers from the MIT Sloan School of Management, the Sean M. Healey & AMG Center for ALS at Massachusetts ...

Tech billionaire Elon Musk’s Neuralink is one of the most talked about players in the BCI field, but the first product to ...

ALS is a slow progressing disease that doesn’t show symptoms right away. Dropping things often can be an early sign.

Unlike previous systems that convert brain signals into text, this BCI synthesizes actual speech almost instantaneously. The ...